Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Acasti Pharma (NQ: ACST ) 2.450 +0.050 (+2.08%) Streaming Delayed Price Updated: 3:58 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 8,483 Open 2.440 Bid (Size) 2.360 (2) Ask (Size) 2.500 (20) Prev. Close 2.400 Today's Range 2.400 - 2.500 52wk Range 1.720 - 3.590 Shares Outstanding 44,612,831 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025 August 09, 2024 ACST stock results show that Acasti Pharma beat analyst estimates for earnings per share the first quarter of 2025. Via InvestorPlace ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024 June 21, 2024 ACST stock results show that Acasti Pharma beat analyst estimates for earnings per share the fourth quarter of 2024. Via InvestorPlace Performance YTD -11.23% -11.23% 1 Month -13.43% -13.43% 3 Month -6.84% -6.84% 6 Month -27.30% -27.30% 1 Year +21.59% +21.59% More News Read More Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 June 18, 2024 Via InvestorPlace The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom May 23, 2024 Via InvestorPlace Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 26, 2023 Via Benzinga Recap: Acasti Pharma Q4 Earnings June 23, 2023 Via Benzinga Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 18, 2024 Via Benzinga Why Acasti Pharma (ACST) Stock Is Exploding Higher September 26, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday May 09, 2023 Via InvestorPlace Acasti Pharma's Earnings Outlook February 13, 2023 Via Benzinga Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 05, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday March 22, 2023 Via InvestorPlace Acasti Pharma Reports Third Quarter 2023 Operational Results February 14, 2023 From Acasti Pharma, Inc. Via GlobeNewswire Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule January 25, 2023 From Acasti Pharma, Inc. Via GlobeNewswire Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 January 24, 2023 From Acasti Pharma, Inc. Via GlobeNewswire Earnings Scheduled For February 14, 2023 February 14, 2023 Via Benzinga Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast January 17, 2023 Via Newsfile Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18 January 13, 2023 From Acasti Pharma, Inc. Via GlobeNewswire Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket January 06, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday January 06, 2023 Via InvestorPlace Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures January 05, 2023 From Acasti Pharma, Inc. Via GlobeNewswire Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia December 28, 2022 From Acasti Pharma, Inc. Via GlobeNewswire Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session December 23, 2022 Via Benzinga Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket December 23, 2022 Via Benzinga Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN) December 22, 2022 From Acasti Pharma, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.